Sataroopa Mishra, Saurabh Kumar Gupta, Sivasubramanian Ramakrishnan
Endothelin receptor blockers are the mainstay of treatment for pulmonary arterial hypertension. These drugs produce pulmonary vasodilation and reduce smooth muscle proliferation by blocking endothelin receptors on pulmonary vascular smooth muscles. Bosentan is the most studied and most widely used endothelin receptor blocker. It is the only drug of this class which is approved for use in children. Nonetheless, better side effect profile and cost effectivity has prompted many to prefer ambrisentan and macitentan over bosentan. This review focuses on the practical aspects of bosentan, ambrisentan and macitentan therapeutics.
Published Date: 2021-09-06;